60 Degrees Pharmaceuticals, Inc. (SXTP)
SXTP moved a median of -0.65% 30 minutes after news, and -1.29% by the close. How SXTP actually reacts to news — the realized, point-in-time move the market made, measured across 231 labeled events over the last three years with zero look-ahead.
SXTP’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 36% | 214 |
| 30-min | -0.65% | 40% | 228 |
| 60-min | -0.81% | 41% | 231 |
| to close | -1.29% | 38% | 228 |
| Middle 50% of SXTP reactions | -3.11% to +1.53% |
|---|---|
| Median reaction (30-min) | -0.65% |
| Measured reactions | 231 |
Half of all 60 Degrees Pharmaceuticals, Inc. news events land between -3.11% and +1.53% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when SXTP moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to SXTP's baseline. Nothing else.
Recent SXTP events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| 60 Degrees Pharmaceuticals Plans January 2027 Hospitalized Babesiosis Data Readout; Will Seek Pre-sNDA Meeting with FDA | Press release | GlobeNewswire | -9.12% | +3.74% | |
| Form 8-K 60 DEGREES PHARMACEUTICA For: Oct 06 | SEC filing · Form 8-K | SEC EDGAR | -9.12% | +3.74% | |
| 60 Degrees Pharmaceuticals Announces Date for Hospitalized Babesiosis Study Interim Data Release and Key Opinion Leader Webinar | Press release | GlobeNewswire | -0.38% | -3.10% | |
| Form 8-K 60 DEGREES PHARMACEUTICA For: Sep 12 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +11.54% | |
| Form 8-K 60 DEGREES PHARMACEUTICA For: Sep 12 | SEC filing · Form 8-K | SEC EDGAR | -0.01% | -5.96% | |
| Form 8-K 60 DEGREES PHARMACEUTICA For: Sep 08 | SEC filing · Form 8-K | SEC EDGAR | +0.41% | -3.67% | |
| 60 Degrees Pharmaceuticals Announces Participation in H.C. Wainwright 28th Annual Global Investment Conference | Press release | GlobeNewswire | -6.06% | -6.05% | |
| Form EFFECT 60 DEGREES PHARMACEUTICA | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | -3.57% | |
| Form DEL AM 60 DEGREES PHARMACEUTICA | SEC filing · Form DEL | SEC EDGAR | — | -2.70% | |
| 60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results | Press release | GlobeNewswire | +4.24% | +1.27% | |
| Form 10-Q 60 DEGREES PHARMACEUTICA For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.43% | +2.14% | |
| Form S-3 60 DEGREES PHARMACEUTICA | SEC filing · Form S-3 | SEC EDGAR | -7.56% | -9.24% | |
| Form 8-K 60 DEGREES PHARMACEUTICA For: Aug 05 | SEC filing · Form 8-K | SEC EDGAR | -3.39% | -5.08% | |
| Form 8-K 60 DEGREES PHARMACEUTICA For: Jul 30 | SEC filing · Form 8-K | SEC EDGAR | -5.20% | -2.40% | |
| 60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced At-the-Market Under Nasdaq Rules | Press release | GlobeNewswire | -19.42% | -10.07% | |
| 60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026 | Press release | GlobeNewswire | +5.92% | -17.22% | |
| Form 8-K 60 DEGREES PHARMACEUTICA For: Jul 20 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +1.95% | |
| Form 8-K 60 DEGREES PHARMACEUTICA For: Jul 07 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -3.11% | |
| 60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases | Press release | GlobeNewswire | -1.97% | +1.97% | |
| Form DEF 14A 60 DEGREES PHARMACEUTICA For: Aug 05 | SEC filing · Form DEF | SEC EDGAR | +0.00% | -0.59% | |
| 60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue | Press release | GlobeNewswire | +3.31% | +5.42% | |
| 60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement | Press release | GlobeNewswire | -4.96% | -2.13% | |
| Form PRE 14A 60 DEGREES PHARMACEUTICA For: Jun 08 | SEC filing · Form PRE | SEC EDGAR | +0.70% | -2.80% | |
| Form 8-K 60 DEGREES PHARMACEUTICA For: Jun 03 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.69% | |
| 60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis | Press release | GlobeNewswire | -1.09% | +1.35% | |
| Form 8-K 60 DEGREES PHARMACEUTICA For: May 13 | SEC filing · Form 8-K | SEC EDGAR | -2.70% | -4.73% | |
| 60 Degrees Pharmaceuticals Announces First Quarter 2026 Results | Press release | GlobeNewswire | -2.03% | -6.08% | |
| Form 10-Q 60 DEGREES PHARMACEUTICA For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -2.03% | -6.08% | |
| RedChip's Biotech Investor Conference Replays Now Available | Press release | ACCESS Newswire | +2.25% | +3.37% | |
| 60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel Website | Press release | GlobeNewswire | +3.65% | -10.50% | |
| Infrastructure Capital and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV | Press release | ACCESS Newswire | +1.12% | +3.91% | |
| RedChip Showcases Public Companies Driving Biotech Innovation at April 16 Virtual Investor Conference | Press release | ACCESS Newswire | +1.12% | +3.91% | |
| 60 Degrees Pharmaceuticals Announces 2025 Annual Results | Press release | GlobeNewswire | -8.03% | +8.03% | |
| Form 10-K 60 DEGREES PHARMACEUTICA For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -8.03% | +8.03% | |
| Form 8-K 60 DEGREES PHARMACEUTICA For: Mar 20 | SEC filing · Form 8-K | SEC EDGAR | -1.05% | -4.19% | |
| 60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract | Press release | GlobeNewswire | -3.08% | -6.61% | |
| Form 8-K 60 DEGREES PHARMACEUTICA For: Mar 13 | SEC filing · Form 8-K | SEC EDGAR | +3.75% | -6.64% | |
| Form 8-K 60 DEGREES PHARMACEUTICA For: Mar 12 | SEC filing · Form 8-K | SEC EDGAR | -5.74% | -13.72% | |
| 60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial | Press release | GlobeNewswire | -1.39% | +49.07% | |
| 60 Degrees Pharmaceuticals and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV | Press release | ACCESS Newswire | +1.72% | +7.24% | |
| Form 8-K 60 DEGREES PHARMACEUTICA For: Feb 11 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +1.80% | |
| 60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership | Press release | GlobeNewswire | +0.27% | -1.89% | |
| 60 Degrees Pharmaceuticals Exercises License Option with Florida State University for Large-Scale Purification of Castanospermine for Non-Rx Use | Press release | GlobeNewswire | -5.65% | +8.79% | |
| Form 8-K 60 DEGREES PHARMACEUTICA For: Jan 20 | SEC filing · Form 8-K | SEC EDGAR | +6.29% | +44.91% | |
| 60 Degrees Pharmaceuticals Announces Partnership with Runway Health to Provide International Travelers Direct Access to ARAKODA® for Malaria Prevention | Press release | GlobeNewswire | +25.33% | -16.00% | |
| Form 8-K 60 DEGREES PHARMACEUTICA For: Jan 14 | SEC filing · Form 8-K | SEC EDGAR | +25.33% | -16.00% | |
| 60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio | Press release | GlobeNewswire | +2.21% | +3.72% | |
| Form 8-K 60 DEGREES PHARMACEUTICA For: Jan 08 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +1.49% | |
| 60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State | Press release | GlobeNewswire | -3.71% | -23.93% | |
| 60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026 | Press release | GlobeNewswire | -0.49% | -10.82% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the SXTP section they belong to.
Where else SXTP is measured.
SXTP earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is 60 Degrees Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled SXTP news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 231 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 40% of SXTP's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does SXTP's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.